Multicenter Double-Blind Randomized Controlled Trial to Evaluate the Effectiveness and Safety of Bortezomib as a Treatment for Refractory Systemic Lupus Erythematosus.
Author | |
---|---|
Abstract |
:
To evaluate the efficacy and safety of bortezomib for treating systemic lupus erythematosus (SLE), in patients whose disease activity could not be controlled. |
Year of Publication |
:
2018
|
Journal |
:
Modern rheumatology
|
Number of Pages |
:
1-20
|
Date Published |
:
2018
|
ISSN Number |
:
1439-7595
|
URL |
:
http://www.tandfonline.com/doi/full/10.1080/14397595.2018.1432331
|
DOI |
:
10.1080/14397595.2018.1432331
|
Short Title |
:
Mod Rheumatol
|
Download citation |